Brimonidine suspension - Sun Pharma Advanced Research Company

Drug Profile

Brimonidine suspension - Sun Pharma Advanced Research Company

Alternative Names: Brimonidine Tartrate 0.35%

Latest Information Update: 26 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sun Pharma Advanced Research Company
  • Class Antiglaucomas; Antihypertensives; Eye disorder therapies; Quinoxalines
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Glaucoma

Most Recent Events

  • 08 Jun 2017 Sun Pharma Advanced Research Company completes a phase II trial in Glaucoma in Bulgaria (Ophthalmic) (EudraCT2015-005540-34)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top